TY - JOUR
T1 - Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial
AU - Govsyeyev, Nicholas
AU - Nehler, Mark R.
AU - Low Wang, Cecilia C.
AU - Kavanagh, Sarah
AU - Hiatt, William R.
AU - Long, Chandler
AU - Jones, W. Schuyler
AU - Fowkes, F. Gerry R.
AU - Berger, Jeffrey S.
AU - Baumgartner, Iris
AU - Patel, Manesh R.
AU - Goodney, Philip P.
AU - Beckman, Joshua A.
AU - Katona, Brian G.
AU - Mahaffey, Kenneth W.
AU - Blomster, Juuso
AU - Norgren, Lars
AU - Bonaca, Marc P.
N1 - Funding Information:
N.G. was supported by National Institutes of Health/National Center for Advancing Translational Sciences Colorado CTSI Grant Number UL1 TR002535. Contents are the authors' sole responsibility and do not necessarily represent official National Institutes of Health views. This entity was not involved in the study design or collection, analysis, or interpretation of data. This grant supports a Master of Clinical Science degree from the University of Colorado awarded to Nicholas Govsyeyev. There was no involvement with manuscript writing or the decision to submit the manuscript for publication.M.P.B. was supported by the American Heart Association Strategically Focused Research Network in Vascular Disease under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association. This entity was not involved in the study design or collection, analysis, or interpretation of data. There was no involvement with manuscript writing or the decision to submit the manuscript for publication.The EUCLID trial was funded by AstraZeneca. This sponsor was not involved with data collection, analysis, or interpretation of data for this manuscript. The sponsor reviewed the manuscript prior to publication though had no involvement with the decision to submit the manuscript for publication.Author conflict of interest: M.R.N reports grants from Bayer, grants from Janssen, during the conduct of the study; other from CPC Research, outside the submitted work. S.K. receives consulting fees from UCB Pharma, Novartis Gene Therapies, Karuna Therapeutics, Zosano Pharmaceuticals, and Worldwide Clinical Trials. W.R.H. has passed away. He reported research grants from Bayer, Janssen, Amgen, AstraZeneca, and the National Institutes of Health. W.S.J. reports research grants from Bayer, Boehringer Ingelheim, the Doris Duke Charitable Foundation, the National Institutes of Health, and the Patient-Centered Outcomes Research Institute and advisory boards/other from Bayer, Bristol-Myers Squibb, and Janssen Pharmaceuticals. F.G.R.F. belongs to the advisory boards for AstraZeneca, Bayer, and Merck. J.S.B. reports institutional research grants from AstraZeneca, the National Heart, Lung, and Blood Institute, and the American Heart Association and consulting fees from Janssen, Merck, and Takeda. I.B. reports institutional research grants from Abbott Vascular, Cook, and Boston Scientific. M.R.P. reports research grants from the Agency for Healthcare Research and Quality, AstraZeneca, Bayer, Jansen, Procyrion, and Heartflow and honoraria/advisory board for Bayer, Janssen, and AstraZeneca. J.A.B. reports consulting with Amgen, Bayer, JanOne, and Janssen; receives research funding from Bristol Myers Squibb; and serves on the Data Safety Monitoring Committee for Janssen. B.G.K. is an employee of AstraZeneca, LP. K.W.M. reports research grants from Afferent, Amgen, Apple, Inc, AstraZeneca, Cardiva Medical, Inc, Ferring, Google (Verily), Johnson & Johnson, Luitpold, Medtronic, Merck, the National Institutes of Health, Novartis, Sanofi, and St. Jude and consulting or other services (including Continuing Medical Education) for Abbott, Amgen, Anthos, AstraZeneca, Baim Institute, Boehringer Ingelheim, CSL Behring, Elsevier, Intermountain Health, Johnson & Johnson, Medscape, Mount Sinai, Mundi Pharma, Myokardia, the National Institutes of Health, Novartis, Novo Nordisk, Portola, Regeneron, Sanofi, SmartMedics, and Theravance. J.B. is a former employee of AstraZeneca. L.N. reports honoraria/advisory board/steering committees from AnGes, Bayer, Cesca, and Pluristem. M.P.B. reports grant support to CPC Clinical Research from Bayer AG and Janssen Pharmaceuticals; grants from Amgen, AstraZeneca, Merck, Novo Nordisk, Pfizer, and Sanofi, outside the submitted work. The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
Funding Information:
N.G. was supported by National Institutes of Health / National Center for Advancing Translational Sciences Colorado CTSI Grant Number UL1 TR002535 . Contents are the authors' sole responsibility and do not necessarily represent official National Institutes of Health views. This entity was not involved in the study design or collection, analysis, or interpretation of data. This grant supports a Master of Clinical Science degree from the University of Colorado awarded to Nicholas Govsyeyev. There was no involvement with manuscript writing or the decision to submit the manuscript for publication.
Funding Information:
M.P.B. was supported by the American Heart Association Strategically Focused Research Network in Vascular Disease under award numbers 18SFRN3390085 (BWH-DH SFRN Center) and 18SFRN33960262 (BWH-DH Clinical Project). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association. This entity was not involved in the study design or collection, analysis, or interpretation of data. There was no involvement with manuscript writing or the decision to submit the manuscript for publication.
Funding Information:
The EUCLID trial was funded by AstraZeneca . This sponsor was not involved with data collection, analysis, or interpretation of data for this manuscript. The sponsor reviewed the manuscript prior to publication though had no involvement with the decision to submit the manuscript for publication.
Publisher Copyright:
© 2021 Society for Vascular Surgery
PY - 2022/2
Y1 - 2022/2
N2 - Objective: Amputation remains a frequent and feared outcome in patients with peripheral artery disease (PAD). Although typically characterized as major or minor on the extent of tissue loss, the etiologies and outcomes after amputation by extent are not well-understood. In addition, emerging data suggest that the drivers and outcomes of amputation in patients with PAD may differ in those with and without diabetes mellitus (DM). Methods: The EUCLID trial randomized 13,885 patients with symptomatic PAD, including 5345 with concomitant diabetes, to ticagrelor or clopidogrel and followed them for long-term outcomes. Amputations were prospectively reported by trial investigators. Their primary and contributing drivers were adjudicated using safety data, including infection, ischemia, or multifactorial etiologies. Outcomes following major and minor amputations were analyzed, including recurrent amputation, major adverse limb events, adverse cardiovascular events, and mortality. Multivariable logistic regression models were used to identify independent predictors of minor amputations. Analyses were performed overall and stratified by the presence or absence of DM at baseline. Results: Of the patients randomized, 398 (2.9%) underwent at least one lower extremity nontraumatic amputation, for a total of 511 amputations (255 major and 256 minor) over a median of 30 months. A history of minor amputation was the strongest independent predictor for a subsequent minor amputation (odds ratio, 7.29; 95% confidence interval, 5.17-10.30; P < .001) followed by comorbid DM (odds ratio, 4.60; 95% confidence interval, 3.16-6.69; P < .001). Compared with patients who had a major amputation, those with a minor amputation had similar rates of subsequent major amputation (12.2% vs 13.6%), major adverse limb events (15.1% vs 14.9%), and major adverse cardiovascular events (17.6% vs 16.3%). Ischemia alone was the primary driver of amputation (51%), followed by infection alone (27%), and multifactorial etiologies (22%); however, infection was the most frequent driver in those with DM (58%) but not in those without DM (15%). Conclusions: Outcomes after amputation remain poor regardless of whether they are categorized as major or minor. The pattern of amputation drivers in PAD differs by history of DM, with infection being the dominant etiology in those with DM and ischemia in those without DM. Greater focus is needed on the prognostic importance of minor amputation and of the multifactorial etiologies of amputation in PAD. Nomenclature with anatomical description of amputations and eliminating terms “major” or “minor” would seem appropriate.
AB - Objective: Amputation remains a frequent and feared outcome in patients with peripheral artery disease (PAD). Although typically characterized as major or minor on the extent of tissue loss, the etiologies and outcomes after amputation by extent are not well-understood. In addition, emerging data suggest that the drivers and outcomes of amputation in patients with PAD may differ in those with and without diabetes mellitus (DM). Methods: The EUCLID trial randomized 13,885 patients with symptomatic PAD, including 5345 with concomitant diabetes, to ticagrelor or clopidogrel and followed them for long-term outcomes. Amputations were prospectively reported by trial investigators. Their primary and contributing drivers were adjudicated using safety data, including infection, ischemia, or multifactorial etiologies. Outcomes following major and minor amputations were analyzed, including recurrent amputation, major adverse limb events, adverse cardiovascular events, and mortality. Multivariable logistic regression models were used to identify independent predictors of minor amputations. Analyses were performed overall and stratified by the presence or absence of DM at baseline. Results: Of the patients randomized, 398 (2.9%) underwent at least one lower extremity nontraumatic amputation, for a total of 511 amputations (255 major and 256 minor) over a median of 30 months. A history of minor amputation was the strongest independent predictor for a subsequent minor amputation (odds ratio, 7.29; 95% confidence interval, 5.17-10.30; P < .001) followed by comorbid DM (odds ratio, 4.60; 95% confidence interval, 3.16-6.69; P < .001). Compared with patients who had a major amputation, those with a minor amputation had similar rates of subsequent major amputation (12.2% vs 13.6%), major adverse limb events (15.1% vs 14.9%), and major adverse cardiovascular events (17.6% vs 16.3%). Ischemia alone was the primary driver of amputation (51%), followed by infection alone (27%), and multifactorial etiologies (22%); however, infection was the most frequent driver in those with DM (58%) but not in those without DM (15%). Conclusions: Outcomes after amputation remain poor regardless of whether they are categorized as major or minor. The pattern of amputation drivers in PAD differs by history of DM, with infection being the dominant etiology in those with DM and ischemia in those without DM. Greater focus is needed on the prognostic importance of minor amputation and of the multifactorial etiologies of amputation in PAD. Nomenclature with anatomical description of amputations and eliminating terms “major” or “minor” would seem appropriate.
KW - Amputation
KW - Diabetes mellitus
KW - Infection
KW - Lower extremity
KW - Peripheral artery disease
UR - http://www.scopus.com/inward/record.url?scp=85122984303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122984303&partnerID=8YFLogxK
U2 - 10.1016/j.jvs.2021.08.096
DO - 10.1016/j.jvs.2021.08.096
M3 - Article
C2 - 34597783
AN - SCOPUS:85122984303
SN - 0741-5214
VL - 75
SP - 660-670.e3
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
IS - 2
ER -